Patients with a DNMT3A exon 23 mutation were exclusively identified in the intermediate-risk group (39/194, 20%) as compared to CBF and high-risk AML (p<0.001), 27 with a normal karyotype and 12 with various associated abnormalities, the most frequent being an additional copy of the chromosome 8 (3 patients) or 13 (2 patients). This evidence concerns the gene CEBPZ and acute myeloid leukemia.